BET inhibitor Pelabresib and AR inhibitor enzalutamide perturbed pathways in prostate cancer CRPC PDX LuCaP 77CR. BET inhibitor Pelabresib and AR inhibitor enzalutamide perturbed pathways in prostate cancer CRPC PDX LuCaP 77CR
收藏NIAID Data Ecosystem2026-05-01 收录
官方服务：
资源简介：
To study the effect of inhibiting AR and HNF1A/HNF4G activity either alone or in combination on the growth of CRPC PDX LuCaP 77CR. Overall design: LuCaP 77CR tumors were treated with enzalutamide, pelabresib or a combination of pelabresib and enzalutamide and tumor volumes were compared to vehicle control
创建时间：
2024-01-20
